News Servier gets a win for cancer drug Tibsovo, bought in $1.8bn... Just three months after completing its $1.8 billion takeover of Agios' oncology pipeline, Servier has reported pos
News Sanofi’s rare disease drug Cablivi approved in the EU The European Commission has approved Sanofi’s Cablivi, the first treatment for patients with the rare blood-clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP), which is
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
